Literature DB >> 19738131

Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?

Christiane A Voit1, Alexander C J van Akkooi, Gregor Schäfer-Hesterberg, Alfred Schoengen, Paul I M Schmitz, Wolfram Sterry, Alexander M M Eggermont.   

Abstract

PURPOSE: Sentinel node (SN) status is the most important prognostic factor for overall survival (OS) for patients with stage I/II melanoma, and the role of the SN procedure as a staging procedure has long been established. However, a less invasive procedure, such as ultrasound (US) -guided fine-needle aspiration cytology (FNAC), would be preferred. The aim of this study was to evaluate the accuracy of US-guided FNAC and compare the results with histology after SN surgery was performed in all patients. PATIENTS AND METHODS: Four hundred consecutive patients who underwent lymphoscintigraphy subsequently underwent a US examination before the SN procedure. When the US examination showed a suspicious or malignant pattern, patients underwent an FNAC. Median Breslow thickness was 1.8 mm; mean follow-up was 42 months (range, 4 to 82 months). We considered the US-guided FNAC positive if either US and/or FNAC were positive. If US was suggestive of abnormality, but FNAC was negative, the US-guided FNAC was considered negative.
RESULTS: US-guided FNAC identified 51 (65%) of 79 SN metastases. Specificity was 99% (317 of 321), with a positive predictive value of 93% and negative predictive value of 92%. SN-positive identification rate by US-guided FNAC increased from 40% in stage pT1a/b disease to 79% in stage pT4a/b disease. US-guided FNAC detected SN tumors more than 1.0 mm in 86% of cases, SN tumors of 0.1 to 1.0 mm in 46% of cases, and SN tumors less than 0.1 mm in 23% of cases. Estimated 5-year OS rates were 92% for patients with negative US-guided FNAC results and 51% for patients with positive results.
CONCLUSION: US-guided FNAC of SNs is highly accurate. Up to 65% of the patients with SN-positive results in our institution could have been spared an SN procedure.

Entities:  

Mesh:

Year:  2009        PMID: 19738131     DOI: 10.1200/JCO.2008.19.0033

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  20 in total

1.  Robotic inguinal lymph node dissection for melanoma: a novel approach to a complicated problem.

Authors:  G Alan Hyde; Nathan L Jung; Alvaro A Valle; Syamal D Bhattacharya; Christopher E Keel
Journal:  J Robot Surg       Date:  2018-01-06

2.  SLNB in melanoma-DFS a true and cost-effective benefit?

Authors:  Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

Review 3.  Predicting the outcome of melanoma: can we tell the future of a patient's melanoma?

Authors:  Oriol Yélamos; Pedram Gerami
Journal:  Melanoma Manag       Date:  2015-08-10

4.  Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention.

Authors:  Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2014-04-08       Impact factor: 66.675

Review 5.  Primary Melanoma: from History to Actual Debates.

Authors:  Alessandro A E Testori; Stephanie A Blankenstein; Alexander C J van Akkooi
Journal:  Curr Oncol Rep       Date:  2019-12-19       Impact factor: 5.075

Review 6.  Importance of tumor load in the sentinel node in melanoma: clinical dilemmas.

Authors:  Alexander C J van Akkooi; Cornelis Verhoef; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2010-06-22       Impact factor: 66.675

7.  Preoperative ultrasound is not useful for identifying nodal metastasis in melanoma patients undergoing sentinel node biopsy: preoperative ultrasound in clinically node-negative melanoma.

Authors:  Christy Y Chai; Jonathan S Zager; Margaret M Szabunio; Suroosh S Marzban; Alec Chau; Robert M Rossi; Vernon K Sondak
Journal:  Ann Surg Oncol       Date:  2011-12-23       Impact factor: 5.344

8.  Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults.

Authors:  Damon Reed; Ragini Kudchadkar; Jonathan S Zager; Vernon K Sondak; Jane L Messina
Journal:  J Natl Compr Canc Netw       Date:  2013-06-01       Impact factor: 11.908

Review 9.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

10.  Potential cost-effectiveness of US-guided FNAC in melanoma patients as a primary procedure and in follow-up.

Authors:  Alexander C J van Akkooi; Christiane A Voit; Cornelis Verhoef; Alexander M M Eggermont
Journal:  Ann Surg Oncol       Date:  2010-02       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.